Orlance, Inc.
Orlance, Inc. develops a needle-free, powdered vaccine delivery platform focused on DNA and RNA vaccines and immunotherapies. Its core technology, a dry-powder epidermal delivery device, targets the skin's immunologically active layers for effective, dose-sparing, and ambient-stable administration, eliminating the need for cold chain logistics. Orlance advances programs for infectious diseases and cancer immunotherapy, leveraging significant non-dilutive funding and strategic partnerships.
Industries
N/A
Products
Needle-free device for administering powdered nucleic acid vaccines into the epidermal layer of skin, designed for infectious disease and immunotherapy applications.
Needle-free device for administering powdered nucleic acid vaccines into the epidermal layer of skin, designed for infectious disease and immunotherapy applications.
Expertise Areas
- Vaccine delivery systems
- DNA and RNA vaccine development
- Needle-free immunization
- Cancer immunotherapy research
Key Technologies
- Powder-mediated epidermal delivery
- Pressurized microparticle gene gun
- DNA vaccine technology
- RNA vaccine technology
Key People
CEO, Director
CTO, Director
Founder
Director R&D
Program Director, Preclinical Development
Senior Administrative and Financial Manager
CEO, Director
CTO, Director
Founder
Director R&D
Program Director, Preclinical Development
Senior Administrative and Financial Manager
News & Updates
Awarded grant to develop therapeutic vaccine for chronic hepatitis B using needle-free delivery technology.
Received Fast Track SBIR grant for enhanced influenza vaccine project.
Awarded grant for development of gene gun-delivered neoantigen cancer vaccines.
Awarded SBIR grant for optimizing RNA vaccine formulations using needle-free platform.
University of Washington feature on development of universal flu vaccine using epidermal gene gun platform.
Company participation in DARPA BIO Fair.
Awarded grant to develop therapeutic vaccine for chronic hepatitis B using needle-free delivery technology.
Received Fast Track SBIR grant for enhanced influenza vaccine project.
Awarded grant for development of gene gun-delivered neoantigen cancer vaccines.
Awarded SBIR grant for optimizing RNA vaccine formulations using needle-free platform.
University of Washington feature on development of universal flu vaccine using epidermal gene gun platform.
Company participation in DARPA BIO Fair.